EAS 2026 24 - 27 May 2026

A quantitative model to estimate free IL-6 levels among participants treated
with the IL-6 ligand inhibitor ziltivekimab: implications for the ZEUS, HERMES,
and ARTEMIS trials

Authors :

Bibi Toft Hellinghus¹; Katherine Tuttle²; Magnus Fugger¹; Ingo Hilgendorf³; Jesper Falkesgaard Højen¹; Peter Libby⁴; Giovanna Liuzzo⁵; Christian M Matter⁶; Patrick Nolain¹; Paul M Ridker⁷

Affiliations

View Details Hide Details

Download .PDF

Keywords

Cardiovascular Disease

Congress poster

Other

Search Science Hub

Are you a healthcare professional?

A quantitative model to estimate free IL-6 levels among participants treated
with the IL-6 ligand inhibitor ziltivekimab: implications for the ZEUS, HERMES,
and ARTEMIS trials

Search Science Hub

Are you a healthcare professional?

A quantitative model to estimate free IL-6 levels among participants treated with the IL-6 ligand inhibitor ziltivekimab: implications for the ZEUS, HERMES, and ARTEMIS trials

A quantitative model to estimate free IL-6 levels among participants treated
with the IL-6 ligand inhibitor ziltivekimab: implications for the ZEUS, HERMES,
and ARTEMIS trials